What do you think of this analysis by Stifel ?
KERX (11.35) target was lowered by Stifel yesterday -
Keryx Biopharma target lowered to $17 at Stifel; Buy (11.45 ) : Stifel lowers their KERX tgt to $17 from $19 as they believe timing around the completion of additional Part D formulary reviews likely implies the full-impact of any progress on the reimbursement front will not materialize until 3Q15 -- at which point sentiment around pending YE15 P3 CKD data should mitigate some of the characteristic volatility associated with weekly prescription data. Firm lowers PT on these tempered launch projections -- with their ests now conservatively assuming
Super earnings report and guidence. 24% service revenue growth & margins should increase as well. This stock is being controlled & manipulated illegally by shorts. I don't know how, but that's what I believe. This report today was fantastic, and for the first time in history, ANGI is posting nice profits two quarters in a row, with guidence for $.20 GAAP, and with what I come up with $.35-$.40 non gaap adjusted for stock based compensatiion & amortization. Every stock in this sector is being valued on non gaap adjusted EPS, so why not ANGI ?
All companies in the sector give non gaap adjusted EPS numbers. If Angie did that, they'd post around $.35-$.40 in EPS for 2015. Also service revnues up 24% yoy, and membership revenues up 18%- not bad !
Stock was $85 when earnings were only $1.19/qtr. What's going on here ?
To be more specific, how much in earnings before taxes/revenues will they have without a pharma partner ? I understand it would be higher going it themselves, but how much ? I'm thinking around 20%- is that in the ballpark ?
I don't get it
I don't get this stock action for the life of me. EBITDA of $31M would suggest GAAP earnings near $.20 for 2015 & $.40 for 2016. In addition, if we value ANGI on non gaap adjusted EPS, it would be more like $.45 for 2015 & $.70 for 2016. Valuations for other companies in this sector are 30-40 times non gaap adjusted EPS, not GAAP EPS. So why in the world is ANGI so cheap ? I just don't get it.
wallstreet- how do you figure. EBITDA of $31M would mean $.53 EBITDA/share. Also the additional $2M in EBITDA would mean $.035 in additional EPS. Analysts wil have to raise their 15 targets to $.18 GAAP & 2016 to $.39 GAAP. I mean, what PE does this sector recieve ? Looks to me, like most companies in the sector are bringing in 40 PEs or so. ANGI is super cheap here at $6 IMO. Please explain your view using the same fundamental analysis
I was using the wrong fully diluted share count. So if we use 58M shares, then $2M more would mean $.035 more in EPS, or about 25% more than than the analyst expectations of around $.16.